Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $2.75.

Several research firms have commented on PSTI. HC Wainwright reissued a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a report on Tuesday, September 19th. Maxim Group reissued a “buy” rating and issued a $2.00 target price on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. Zacks Investment Research downgraded Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Seaport Global Securities began coverage on Pluristem Therapeutics in a report on Friday. They issued a “buy” rating on the stock. Finally, ValuEngine downgraded Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Pluristem Therapeutics (PSTI) opened at 1.50 on Friday. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $1.65. The company’s market capitalization is $146.21 million. The firm’s 50-day moving average price is $1.33 and its 200 day moving average price is $1.31.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC raised its position in Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,553,800 shares of the biotechnology company’s stock after acquiring an additional 129,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/pluristem-therapeutics-inc-psti-receives-consensus-rating-of-hold-from-brokerages.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.